NSE: TAKE | BSE: 532890

Download real time

9.00 -0.07 (-0.77%)

62.01% Fall from 52W High

59,089 NSE+BSE Volume

NSE 08 Aug, 2025 3:31 PM (IST)

133.1

Market Cap

Below industry Median

0.7

Beta 1Year

Very Low volatility

Take Solutions Ltd. share price target and research reports

Name: Latest research reports of Take Solutions Ltd. authored by Karvy and published by - Trendlyne research reports.
Item: Take Solutions Ltd.
Rating: 5
Author: Karvy

Latest analyst research reports with target prices and PDF download for TAKE, BSE:532890 Take Solutions Ltd.

Take Solutions Ltd.

13 Aug 2018

9.00

-0.77%

Take Solutions Ltd: Waiting to Take Off

Buy: Take Solutions Ltd.

Recommendation Target

Karvy

Good performance: Take Solutions (TAKE) reported good set of numbers for Q1 FY19 with a revenue growth of 32% YoY; while EBITDA was up 41% YoY, EBITDA margin at 20% was up 120 bps YoY and flat on QoQ basis.

Take Solutions Ltd. is trading above its 100 day SMA of 8.9

Take Solutions Ltd.

04 Jun 2018

9.00

-0.77%

Take Solutions Ltd: Strong Revenue Growth Driven by Clinical...

Accumulate: Take Solutions Ltd.

Recommendation Target

Karvy

Strong Revenue Growth Driven by Clinical Business: Take Solutions delivered a revenue growth of 28% YoY in Q4FY18 and 18% for FY18. In USD terms company reported a growth of 22% which is in line with the management guidance. For FY18, the clinical business was up by 42%. The growth in clinical business was mainly driven by the shift in order book towards larger contracts.

Take Solutions Ltd. has lost -53.94% in the last 1 Year

Take Solutions Ltd.

21 Feb 2018

9.00

-0.77%

Take Solutions Ltd: Life Sciences Vertical Delivers Robust P... (Feb 21, 2018)

Buy: Take Solutions Ltd.

Target

Karvy

Life Sciences Vertical Delivers Robust Performance; Growthto be Fuelled by Organic & Inorganic Route; Revenue from Life Sciences vertical was recorded at ~ US$ 197 Mn on a TTM basis, marking a growth of 24.9% YoY. The company's order book under the LifeSciences vertical stood strong at US$ 151 Mn.

Take Solutions Ltd. has lost -23.21% in the last 6 Months

Take Solutions Ltd.

22 May 2017

9.00

-0.77%

Take Solutions Ltd: Company Continues on the Growth Trajecto... (May 22, 2017)

Buy: Take Solutions Ltd.

Recommendation Target

Karvy

Company Continues on the Growth Trajectory; Evolving Regulatory Environment Poses an Attractive Opportunity: Revenue for Take Solutions in FY17 was recorded at Rs. 13,446 Mn registeringa robust growth of 30.5% YoY. The company witnessed a slower pace of growth during Q4FY17. For Q4FY17, Take Solutions recorded revenue of Rs. 3,555 Mn, marking a sequential growth of 3.6%. EBITDA margins saw some pruning in FY17 and were recorded at 19.0% compared to 20.7% in FY16. Order Pipeline for TakeSolutions at the end of FY17 stood strong at US$ 144 Mn, marking a significant improvement from FY16 order book of US$ 103 Mn.

Take Solutions Ltd. is trading above its 100 day SMA of 8.9

Take Solutions Ltd.

06 Dec 2016

9.00

-0.77%

Take Solutions

Take Solutions Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research We attended the analyst meet of Take Solutions (Take), an IT company focused on niche verticals like life sciences (LS). The company highlighted the pharma R&D; landscape and how technology would evolve across drug development life-cycle processes like clinical, regulatory and safety. Pharma R&D; outsourcing, which is currently at ~US$30-33 billion, could grow 7-10% in coming years. The biosimilars market is currently at ~US$3 billion and is expected to grow 7-10x in coming years. New...

Take Solutions Ltd. is trading above its 100 day SMA of 8.9

Take Solutions Ltd.

01 Dec 2016

9.00

-0.77%

TAKE SOLUTIONS LTD

Buy: Take Solutions Ltd.

Rudra Shares and Stock Brokers Ltd

Company continued its strategy to focus and grow in niche segments for improved long term growth and margins. During the year, the Company divested its investments in Applied Clinical Intelligence and TAKE Business Cloud. It also made a strategic acquisition of Ecron Acunova in the last quarter of FY 2016 to further strengthen its offerings in life science domain. Acquisition of Ecron Acunova- Bodes well for company to increase its addressable market size Currently TAKE is providing functional services and software solutions related to clinical data management, regulatory compliance and drug safety, which constitutes just 35% of the pharma R&D; outsourcing. Prior to acquisition of EA, it had marginal presence in clinical trial studies, which is 60% of...

Take Solutions Ltd. is trading above its 100 day SMA of 8.9

Take Solutions Ltd.

10 Jun 2016

9.00

-0.77%

Pick of the Week - Take Solutions Ltd

Buy: Take Solutions Ltd.

HDFC Securities

Buy Take Solutions Ltd at CMP and Add on Dips of Rs. 148 - Rs. 155 for the Sequential Targets of Rs. 202 - Rs. 233

Take Solutions Ltd. has gained 23.12% in the last 3 Months

Take Solutions Ltd.

23 Mar 2016

9.00

-0.77%

Take Solutions Ltd: Improving Life Sciences Business and US Economy Hold Key (Mar 23, 2016)

Hold: Take Solutions Ltd.

Karvy

Growing life sciences business to improve overall margins and drive growth in future: Currently, life sciences business contributes to around 70% of the company's revenue. In Q3FY16, the growth in the Life Sciences order book has resulted in an increase of 20.7% over the previous year in total order book of US$ 80.5 Mn. Take Solutions recently consolidated all their life sciences operations under a new brand Navitas. This will help them further to focus more on life sciences business. We expect the high margin life sciences business which has an EBITDA margin in the range of 25-30% to continue its healthy growth and drive the firm's top line and bottom line.

Take Solutions Ltd. has lost -53.94% in the last 1 Year

Is Take Solutions Ltd. worth buying?

206 Votes:

Buy 77.18%

Sell 14.56%

Hold 8.25%